Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate and compare the changes of cognitive function (as
measured by ADAS-Cog) in the two group of patients with Alzheimer's disease (AD) associated
with and without white matter changes after rivastigmine patch therapy.